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Materials and methods. Retrospective study of 25 patients diagnosed with aggressive desmoid tumor between 2006 until February
2013. We used the STTU database and clinical reports of each patient to analyze the treatment and follow-up. Radiotherapy (RT)
was delivered in photons or electrons using appropriate technique to each site. The median RT dose was 56Gy (Range 50–60Gy).
A systematic pubmed research was conducted and compared to our decisions and results.
Results. From 25 patients 8 were male and 17 were female. The mean age was 34 years old (range 5–58). Tumor location was: 6 in
superior limbs, 14 in inferior limbs, 1 in head and neck and 4 in trunk. The sizes were: <5 cm, 9; 5–10 cm, 10 and >10 cm, 6 patients.
21 patients received surgery as a ﬁrst treatment and 9 recurred. Preoperative RT was indicated when negative margins resection
was impossible, 3 patients were recommended this treatment. Postoperative RT is indicated in high risk of local recurrence due to
positive margins, close margins and in case of high morbidity of further surgical resections. 15 patients received RT. The median
follow up was 8 months, mean 17 (range 6–39) and no recurrences were detected. Other therapies used were: adjuvant tamoxifen
and neoadjuvant imatinib
Conclusions. We received 25 patients in the last 10 years presenting this locally aggressive tumor. Its heterogeneous and uncertain
biological behavior demands a multidisciplinary decision-making. Still we have not reached standard treatment and individu-
alization in each case is always needed. In our experience RT plays an important role in this rare pathology.
http://dx.doi.org/10.1016/j.rpor.2013.03.576
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Introduction. Radiotherapy of retroperitoneal sarcomas remains a technical challenge considering the threshold of contiguous
critical organs tolerance. Intensity Modulated Radiation Therapy (IMRT) is useful in many tumors offering higher conformity and
reducing the dose to healthy tissues. We present here the implementation of IMRT using RapidarcTM (RArIMRT) to patients with
retroperitoneal sarcomas
Material and Methods. Seven patients with different target shapes and volumes were studied. Planning target volume (PTV) was
deﬁned as clinical target volume (CTV) plus 0.5 cm. CTV encompassed gross tumor volume (GTV) plus a 1-cm margin. Five of
them were planned to receive RArIMRT before surgery to a total dose of 50Gy. Prescribed dose was 45Gy for postoperative setting.
A special interest was put in the controlateral or remaining kidney to preserve his function. Dose to spinal cord and small bowel
were minimized as much as possible
Results. Mean PTV was 1985cc (range, 384–6198). In all patients, 95% of the dose covered 99% of the PTV. Forty-six percent of the
remaining kidney received 5Gy (V5) but only for the patient presenting the biggest tumor volume. For the six other patients, V5
were 0 to 2.7%. The dose received by 1% of the kidney was 5.4Gy (range, 3.6–7.6). Maximum dose to the spinal cord was 41Gy.
Portion of the bowel receiving 30, 40, and 50Gy was 26% (range, 11.9–36), 14% (range, 1.7-22), and 4% (range, 0–11), respectively.
All patients but one achieved acceptable results with only one arc. The mean monitor units were 318 (range, 337–395) and the
treatment time was 1.1min for one arc and 2.3min for two arcs
Conclusion. RArIMRT implemented to retroperitoneal sarcomas is feasible irrespective to the shape and the dimension of the
considering volumes. We have now implemented it on rutine in our service.
http://dx.doi.org/10.1016/j.rpor.2013.03.577
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Purpose. Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma arising in the dermoepidermal junction. Inci-
dence increases progressively with age. The median age of diagnosis is 65 years. Usually presents as a painless, induration,
solitary dermal nodule. There is controversy internationally in the relative roles of surgery and RT in treatment. Treatments
regimes are variable. Surgery followed by adjuvant RT to the primary site as well as the lymphatic basin is recommended by
some previous studies
Methods and material. 66 year old male who presented for 1 year with progressive growth mass groin. The biopsy report of
neuroendocrine tumor performing tumor excision and inguinal lymphadenectomy. Is classiﬁed as cT3 cN0 M0 (IIB). We refer to
adjuvant radiotherapy
Results. The primary site is treated with 60Gy in 2Gy fractions to an area of skin that includes the lesion or scar with a ﬁve cm
margin
